4F-MDMB-BINACA (also known asMDMB-4F-BINACA using systematicEMCDDA nomenclature[2] or4F-MDMB-BUTINACA) is anindazole-based syntheticcannabinoid from the indazole-3-carboxamide family.[3] It should not be confused with the amantadine analogue 4F-ABINACA. It has been used as an active ingredient insynthetic cannabis products and sold as adesigner drug since late 2018.[4][5] 4F-MDMB-BINACA is anagonist of theCB1 receptor (EC50 = 7.39 nM),[6] though it is unclear whether it is selective for this target.[7] In December 2019, theUNODC announced scheduling recommendations placing 4F-MDMB-BINACA into Schedule II throughout the world.[8]
The corresponding indole core analogue,4F-MDMB-BICA (4F-MDMB-BUTICA), has also been widely sold as a designer drug by chemical providers on the internet, first being identified in May 2020.[9]
4F-MDMB-BICA
4F-MDMB-BINACA may be confused with a positional isomer of5F-MDMB-PINACA called 4F-MDMB-PINACA, because of the use of the confusing names 5F-ADB and 4F-ADB. These confusing shorter names were not scientifically adopted but were used by websites selling the drugs to the public.
4F-MDMB-BINACA is considered a Schedule I controlled substance as a positional isomer of the Schedule I compound5F-AMB (5F-MMB-PINACA / 5F-AMB-PINACA). There has been charges brought against individuals for possession and distribution of 4F-MDMB-BINACA due to it being a positional isomer of 5F-AMB.[10]
The DEA has temporarily placed 4F-MDMB-BUTICA (the indole core analog of 4F-MDMB-BINACA) into Schedule I status starting on December 12th, 2023, for up to 2 years, during which it's possible the DEA could file for permanent scheduling within those 2 years. If the DEA does not file to permanent placement the temporary Schedule I order will expire on December 12th, 2025.[11]
North Dakota has placed 4F-MDMB-BINACA into Schedule I on 04/27/2023.[12]
^Krotulski AJ, Mohr AL, Kacinko SL, Fogarty MF, Shuda SA, Diamond FX, et al. (September 2019). "4F-MDMB-BINACA: A New Synthetic Cannabinoid Widely Implicated in Forensic Casework".Journal of Forensic Sciences.64 (5):1451–1461.doi:10.1111/1556-4029.14101.PMID31260580.S2CID195770459.
^Cannaert A, Sparkes E, Pike E, Luo JL, Fang A, Kevin RC, et al. (December 2020). "Synthesis andin Vitro Cannabinoid Receptor 1 Activity of Recently Detected Synthetic Cannabinoids 4F-MDMB-BICA, 5F-MPP-PICA, MMB-4en-PICA, CUMYL-CBMICA, ADB-BINACA, APP-BINACA, 4F-MDMB-BINACA, MDMB-4en-PINACA, A-CHMINACA, 5F-AB-P7AICA, 5F-MDMB-P7AICA, and 5F-AP7AICA".ACS Chemical Neuroscience.11 (24):4434–4446.doi:10.1021/acschemneuro.0c00644.PMID33253529.S2CID227246346.
